For instance, Goel et al.’s groundbreaking study showed that blocking CDK4/6 triggers anti-tumor immunity in breast cancer models, resulting in strong CD8+ T-cell infiltration and better tumor rejection when combined with PD-L1 blockade [128,129]. Here, CDK4 is linked to breast carcinoma.